Chronicle Journal: Finance

Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Avrobio Inc (NQ: AVRO)
20.61 USD  +0.37 (+1.83%)
Official Closing Price  /  Updated: 4:00 PM EDT, May 27, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 399,084
Open 20.27
Bid (Size) 10.56 (4)
Ask (Size) 20.95 (1)
Prev. Close 20.24
Today's Range 19.21 - 20.99
52wk Range 9.760 - 29.32
Shares Outstanding 23,149,645
Dividend Yield N/A
Performance
YTD
N/A
N/A
1 Month
+38.60%
+38.60%
3 Month
+9.80%
+9.80%
6 Month
+31.78%
+31.78%
1 Year
+32.20%
+32.20%
Top News
More News
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new preclinical data for AVR-RD-03 for... Read More
from Business Wire News Releases
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new clinical data from its investigational... Read More
from Business Wire News Releases
More News
Read More
AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
from Business Wire News Releases
First Week of November 20th Options Trading For AVROBIO (AVRO)
category Stocks
from Market News Video
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from Business Wire News Releases
AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
from Business Wire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO
from PR Newswire
Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
from Business Wire News Releases
AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020
from Business Wire News Releases
AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally
from Business Wire News Releases
AVROBIO (AVRO) Shares Cross Above 200 DMA
category Stocks
from Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]